Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Related Questions
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you taper corticotropin injections (Acthar) in patients with rheumatologic disease?
Would you stop methotrexate or leflunomide if MCV increases after starting the medication with no other parameters of anemia or leukopenia?
How would you approach using the new vagus nerve stimulator for patients with RA?
How do you manage oral ulcers as a side effect from leflunomide?
In what clinical situations do you consider azathioprine for treatment of inflammatory arthritis?
How do you approach diagnosis in a patient with inflammatory joint symptoms and isolated bilateral CMC joint erosions on x-ray imaging?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
How do you approach dyspnea in a patient with seropositive rheumatoid arthritis with normal imaging findings but abnormal PFT findings (restriction, reduced DLCO)?
